Amylyx, Neopharm announce agreement to distribute oral ALS treatment in Middle East
Click Here to Manage Email Alerts
Amylyx Pharmaceuticals Inc. announced an exclusive license and distribution agreement with Neopharm for the commercialization of ALS therapeutic AMX0035 in Israel, Gaza, West Bank and the Palestinian Authority.
“This agreement with Neopharm is an important step towards expanding AMX0035’s availability in the EMEA (Europe, Middle East and Africa) region, if approved,” Stéphanie Hoffmann-Gendebien, general manager and head of EMEA at Amylyx, stated in a company release. “Our team remains steadfast in our mission to help every eligible person living with ALS gain access to AMX0035.”
According to the release, terms of the agreement stipulate that Neopharm will receive exclusive rights to commercialize AMX0035 — an oral, fixed-dose of sodium phenylbutyrate and ursodoxicoltaurine — in the above-mentioned Middle Eastern territories, and will be responsible for all regulatory filings and obligations required for the registration and reimbursement of the drug.
“The addition of AMX0035 to our portfolio and the opportunity to serve the ALS community in Israel and beyond is an honor,” Efi Shnaidman, general manager of Neopharm Israel, said in the release. “We look forward to working with Amylyx to serve people living with ALS who may benefit from this important new treatment option.”